Sanofi antes up $55M to add protein degradation tech to the R&D playbook as execs look to revive the pipeline
Sanofi is taking a page out of Gilead’s BD strategy book, beating a path to a San Francisco-based biotech that’s begun to build a rep in protein degradation work.
Six months after Gilead jumped aboard Nurix Therapeutic’s platform with a collaboration ticket that cost $45 million upfront and up to $2.5 billion in milestones, the French pharma giant followed up with its own deal to do the same.
As we first reported Wednesday, Sanofi was drawn in by the Third Rock startup’s cancer drug platform, which uses E3 ligases to induce degradation of specific drug targets — a popular field in oncology.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
